We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Successful Use of Mizoribine to Treat Recurrent Corticosteroid-Resistant Palpable Purpura in a Patient With Henoch-Schönlein Purpura Nephritis

Tamihiro Kawakami, MD, PhD; Sayuri Shirai, MD, PhD; Kenjiro Kimura, MD, PhD; Yoshinao Soma, MD, PhD
Arch Dermatol. 2010;146(2):212-213. doi:10.1001/archdermatol.2009.371.
Text Size: A A A
Published online


Mizoribine is a newly developed immunosuppressive agent with few toxic effects.1 The pharmacologic effects of mizoribine are similar to those of another purine biosynthesis inhibitor, mycophenolate mofetil. Published studies have shown positive effects of mizoribine and a favorable safety profile for its use in treating nephrotic syndrome,2 IgA nephropathy,3 and lupus nephritis.1

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Examination revealed palpable purpura on the left arm of the patient (A), which responded to treatment with mizoribine (B).

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections

Care at the Close of Life: Evidence and Experience
Glucocorticoid Therapy

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Evidence Summary and Review 5